Overview

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

Status:
Active, not recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, randomized, Phase 3 study in patients with ductal adenocarcinoma of the pancreas who have failed only one prior line of systemic anti-cancer therapy for advanced pancreatic cancer and have measurable disease.

Phase:

Phase 3

Details

Lead Sponsor:

ERYtech Pharma

Treatments:

Albumin-Bound Paclitaxel
Asparaginase
Gemcitabine
Irinotecan
Leucovorin
Paclitaxel